Coating Comprising A Poly(Ethylene Glycol)-Poly(Lactide-Glycolide-Caprolactone) Interpenetrating Network

ABSTRACT

Implantable medical devices are disclosed. The devices comprise a coating comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. A method of using the implantable device is also provided.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a division of U.S. application Ser. No. 12/101,866,filed on Apr. 11, 2008 and published on Oct. 15, 2009 as U.S. PatentApplication Publication No. 2009-0259302 A1, which is incorporated byreference herein in its entirety, including any drawings.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention is directed to coatings for drug delivery devices, suchas drug delivery vascular stents, and methods for making and using thesame.

2. Description of the State of the Art

Percutaneous transluminal coronary angioplasty (PTCA) is a procedure fortreating heart disease. A catheter assembly having a balloon portion isintroduced percutaneously into the cardiovascular system of a patientvia the brachial or femoral artery. The catheter assembly is advancedthrough the coronary vasculature until the balloon portion is positionedacross the occlusive lesion. Once in position across the lesion, theballoon is inflated to a predetermined size to radially compress againstthe atherosclerotic plaque of the lesion to remodel the lumen wall. Theballoon is then deflated to a smaller profile to allow the catheter tobe withdrawn from the patient's vasculature.

A problem associated with the above procedure includes formation ofintimal flaps or torn arterial linings which can collapse and occludethe conduit after the balloon is deflated. Moreover, thrombosis andrestenosis of the artery may develop over several months after theprocedure, which may require another angioplasty procedure or a surgicalby-pass operation. To reduce the partial or total occlusion of theartery by the collapse of arterial lining and to reduce the chance ofthe development of thrombosis and restenosis, a stent is implanted inthe lumen to maintain the vascular patency.

Stents are used not only as a mechanical intervention but also as avehicle for providing biological therapy. As a mechanical intervention,stents act as scaffoldings, functioning to physically hold open and, ifdesired, to expand the wall of the passageway. Typically, stents arecapable of being compressed, so that they can be inserted through smallvessels via catheters, and then expanded to a larger diameter once theyare at the desired location. Examples in patent literature disclosingstents which have been applied in PTCA procedures include stentsillustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No.4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued toWiktor.

Biological therapy can be achieved by medicating the stents. Medicatedstents provide for the local administration of a therapeutic substanceat the diseased site. In order to provide an efficacious concentrationto the treated site, systemic administration of such medication oftenproduces adverse or toxic side effects for the patient. Local deliveryis a preferred method of treatment in that smaller total levels ofmedication are administered in comparison to systemic dosages, but areconcentrated at a specific site. Local delivery thus produces fewer sideeffects and achieves more favorable results. One proposed method formedicating stents involves the use of a polymeric carrier coated ontothe surface of a stent. A solution which includes a solvent, a polymerdissolved in the solvent, and a therapeutic substance dispersed in theblend is applied to the stent. The solvent is allowed to evaporate,leaving on the stent surface a coating of the polymer and thetherapeutic substance impregnated in the polymer.

Local administration of therapeutic agents via stents has shown somefavorable results in reducing restenosis. However, the properties ofstent coatings can be improved. For example, in a drug delivery coatingof polylactic acid or poly(lactic acid-co-glycolic acid), phaseseparation of the drug and polymers has been observed, which can lead toundesirable level of control of the release of drug. Therefore, there isa need for materials that provide a better way for controlling drugrelease and improving coating integrity post high temperature processingsuch as EtO sterilization and stent crimping.

Embodiments of the present invention described below address the aboveidentified issues and needs.

SUMMARY

In according to an aspect of the present invention, it is provided amethod for fabricating a coating for an implantable medical device. Themethod comprises forming a coating on the device, the coating comprisingan interpenetrating network (IPN) or semi-IPN, wherein the IPN orsemi-IPN comprises poly(ethylene glycol) (PEG) and an aliphaticpolyester copolymer. The coating can be formed by various methods. Insome embodiments, forming a coating comprises crosslinking the PEGand/or the aliphatic polyester copolymer. In some other embodiments,forming a coating comprises crosslinking the PEG and/or the aliphaticpolyester copolymer with a bifunctional or multifunctional crosslinkingagent. In some embodiments, the aliphatic polyester copolymer cancomprise an electronic unsaturation, and forming a coating comprisescrosslinking the aliphatic polyester copolymer.

In some embodiments, the aliphatic polyester copolymer can compriseD,L-lactide or L-lactide. In some embodiments, the aliphatic polyestercopolymer can comprise glycolide (GA). In some embodiments, thealiphatic polyester copolymer can comprisepoly(L-lactide-co-glycolide-co-caprolactone) (PLGACL) orpoly(D,L-lactide-co-glycolide-co-caprolactone) (PDLA-GA-CL),poly(lactide-co-glycolide) (PLGA), or poly(butylene succinate). Wherethe IPN or semi-IPN comprises both lactide and glycolide, the lactideand glycolide can have different molar ratios, e.g., a molar ratio oflactide to glycolide ranging from about 50% to about 90% such as 75:25.

The IPN or semi-IPN can comprise various levels of PEG. In someembodiments, the IPN or semi-IPN comprises from about 1% to about 40%PEG by mass of the IPN or semi-IPN. In some embodiments, the IPN orsemi-IPN comprises from about 2% to about 25% PEG by mass of the IPN orsemi-IPN. In some further embodiments, the IPN or semi-IPN comprisesfrom about 2% to about 10% PEG by mass of the IPN or semi-IPN.

The coating can further include a bioactive agent such as a drug. Thebioactive agent and the IPN or semi-IPN can have different drug:polymer(D:P) ratio by weight. Examples of such ratios of the bioactive agent tothe IPN or semi-IPN can be from about 1:1 to about 1:5. Examples of thebioactive agent are paclitaxel, docetaxel, estradiol, 17-beta-estradiol,nitric oxide donors, super oxide dismutases, super oxide dismutasesmimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO),biolimus, tacrolimus, dexamethasone, dexamethasone acetate, rapamycin,rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, Biolimus A9(Biosensors International, Singapore), AP23572 (Ariad Pharmaceuticals),γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin,feno fibrate, prodrugs thereof, co-drugs thereof, or combinationsthereof.

The implantable device can be any implantable device. An example of theimplantable device is a stent or a bioabsorbable stent.

In according to another aspect of the present invention, it is providedan implantable medical device comprising a coating. Embodiments of thecoating are as described above.

In according to another aspect of the present invention, it is provideda method, the method comprises implanting an implantable device.Embodiments of the implantable device are as described above.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1F show scanning electronic microscope (SEM) images of coatingsformed of poly(ethylene glycol)-poly(lactide-co-glycolide)interpenetrating network.

FIG. 2 shows release rate profiles of everolimus from coatings formedfrom various PEG-PLGA IPN compositions.

DETAILED DESCRIPTION

In accordance with an aspect of the present invention, it is provided acoating on an implantable device. The coating includes a bioactive agentand an interpenetrating network (IPN) or a semi-IPN comprisingpolyethylene glycol (PEG) and at least one aliphatic polyester. The IPNor semi-IPN will entrap the drug and minimize bulk erosion of thepolymer matrix and therefore provides zero order release of the drug bycontrolled erosion.

In some embodiments, the IPN or semi-IPN ispoly(lactide-co-glycolide-co-caprolactone) (PLGACL) (PEG/PLGACL-IPN) ora semi-interpenetrating network of PEG and PLGACL (PEG/PLGACL-semi-IPN).A coating formed of such an IPN or semi-IPN can have tunable drugrelease or coating properties. For example, by varying the ratio of PEGand PLGACL as well the ratios of lactide to glycolide and caprolactonein the polymer system, the rate and duration of drug release can becontrolled. In addition, varying composition of the PEG and PLGA can betailored to impart elasticity to the coating for achieving goodintegrity of the coating and to control degradation of the coatingmaterial. Lactide units in the IPN or semi-IPN also cause the coating tobe more robust for high temperature processing such as EtO sterilizationand stent crimping. (SEE GRAPH ON RELEASE RATE FOR THREE DIFFERENT IPNSAMPLES).

In some embodiments, the IPN or semi-IPN can be constructed usingPEG-co-poly(butylene succinate) and PLGA or constructed usingPEG-co-PLGA with PLGA.

The IPN or semi-IPN described herein can have different concentration ofPEG. PEG is a hydrophilic and non-fouling polymer. PEG in the IPN orsemi-IPN thus will impart a degree of hydrophilicity and non-foulingproperty that is directly related to the content of PEG in the IPN orsemi-IPN. Generally, an IPN or semi-IPN can have about a PEG contentfrom about % to 40% by mass, preferably about 2% to about 25% by mass,and most preferably about 2% to about 10% by mass, of the total weightof the IPN or semi-IPN.

The polyester polymer imparts hydrophobicity, mechanical strength,elasticity to an IPN or semi-IPN. Polyester polymers have different rateof degradation. Generally, as compared to lactide, glycolide imparts arelatively faster rate of degradation to the polyester. An IPN orsemi-IPN having a higher content of glycolide generally degrades fasterwhile an IPN or semi-IPN having a higher content of lactide is generallymore elastic. Therefore, when an IPN or semi-IPN includes both glycolideand lactide, the molar ratio of lactide to glycolide can be from about50% to about 90%. The lactide can be racemic-lactide, a mixture ofD-lactide and L-lactide or L-lactide or D-Lactide.

The IPN or semi-IPN can be included in a layer of coating on animplantable device alone or with a bioactive agent as a drug deliverymatrix or drug reservoir layer. In some embodiments, a coating includingthe IPN or semi-IPN described herein can include an amorphous primerlayer so as to improve adhesion of the coating to the surface ofimplantable device having the coating. In some embodiments, theamorphous primer layer can be bioabsorbable or non-absorbable. In someembodiments, the primer layer can be formed ofpoly(D,L-lactide-co-glycolide) (PDLGA) with a molar ratio of lactide toglycolide of about 75:25.

As used herein, the term IPN refers to a polymer network comprising twoor more polymers which are at least partially interlaced on a molecularscale but not covalently bonded to each other and cannot be separatedunless chemical bonds are broken. Generally, the three conditions foreligibility as an IPN are: (1) the two polymers are synthesized and/orcrosslinked in the presence of the other, (2) the two polymers havesimilar kinetics, and (3) the two polymers are not dramatically phaseseparated. The term “semi-IPN” refers to a polymer network of two ormore polymers wherein at least one polymer is crosslinked and at leastone polymer is uncrosslinked.

Formation of an IPN or semi-IPN can be achieved by well documentedmethods. Generally, forming an IPN involves crosslinking of polymers inthe IPN construct via crosslinking of the functional groups in thepolymers with or without a crosslinking agent.

For example, crosslinking between polymer chains can happen using abi-functional or multifunctional crosslinking agent or linking agent.The crosslinking agent will cause polymers to crosslink, thereby formingthe IPN or semi-IPN. In some embodiments, crosslinking can occur bycuring of a coating at an elevated temperature comprising curablepolymers. An elevated temperature, as used herein, refers to atemperature higher than the ambient temperature.

Linking agents useful for forming an IPN or semi-IPN described here canbe any molecules having two or more functional groups. Such functionalgroups include, but are not limited to, hydroxyl, thiol, carboxylicacid, sulfonic acid, sulfate, phosphonic acid, phosphate, amino,aldehydes, isocyanate, compounds with two unsaturated groups such asdiacrylate, dimethacrylate or compounds with two vinyl groups or twoallyl groups. Exemplary linking agents include, but are not limited to,glutaraldehyde, N,N′-methylenebisacrylamide (BisAAM), etc.

Definitions

Wherever applicable, the definitions to some terms used throughout thedescription of the present invention as provided below shall apply.

The terms “biologically degradable” (or “biodegradable”), “biologicallyerodable” (or “bioerodable”), “biologically absorbable” (or“bioabsorbable”), and “biologically resorbable” (or “bioresorbable”), inreference to polymers and coatings, are used interchangeably and referto polymers and coatings that are capable of being completely orsubstantially completely degraded, dissolved, and/or eroded over timewhen exposed to physiological conditions and can be gradually resorbed,absorbed and/or eliminated by the body, or that can be degraded intofragments that can pass through the kidney membrane of an animal (e.g.,a human), e.g., fragments having a molecular weight of about 40,000Daltons (40 kDa) or less. The process of breaking down and eventualabsorption and elimination of the polymer or coating can be caused by,e.g., hydrolysis, metabolic processes, oxidation, enzymatic processes,bulk or surface erosion, and the like. Conversely, a “biostable” polymeror coating refers to a polymer or coating that is not biodegradable.

Whenever the reference is made to “biologically degradable,”“biologically erodable,” “biologically absorbable,” and “biologicallyresorbable” stent coatings or polymers forming such stent coatings, itis understood that after the process of degradation, erosion,absorption, and/or resorption has been completed or substantiallycompleted, no coating or substantially little coating will remain on thestent. Whenever the terms “degradable,” “biodegradable,” or“biologically degradable” are used in this application, they areintended to broadly include biologically degradable, biologicallyerodable, biologically absorbable, and biologically resorbable polymersor coatings.

“Physiological conditions” refer to conditions to which an implant isexposed within the body of an animal (e.g., a human). Physiologicalconditions include, but are not limited to, “normal” body temperaturefor that species of animal (approximately 37° C. for a human) and anaqueous environment of physiologic ionic strength, pH and enzymes. Insome cases, the body temperature of a particular animal may be above orbelow what would be considered “normal” body temperature for thatspecies of animal. For example, the body temperature of a human may beabove or below approximately 37° C. in certain cases. The scope of thepresent invention encompasses such cases where the physiologicalconditions (e.g., body temperature) of an animal are not considered“normal.” In the context of a blood-contacting implantable device, a“prohealing” drug or agent refers to a drug or agent that has theproperty that it promotes or enhances re-endothelialization of arteriallumen to promote healing of the vascular tissue.

As used herein, a “co-drug” is a drug that is administered concurrentlyor sequentially with another drug to achieve a particularpharmacological effect. The effect may be general or specific. Theco-drug may exert an effect different from that of the other drug, or itmay promote, enhance or potentiate the effect of the other drug.

As used herein, the term “prodrug” refers to an agent rendered lessactive by a chemical or biological moiety, which metabolizes into orundergoes in vivo hydrolysis to form a drug or an active ingredientthereof. The term “prodrug” can be used interchangeably with terms suchas “proagent”, “latentiated drugs”, “bioreversible derivatives”, and“congeners”. N. J. Harper, Drug latentiation, Prog Drug Res., 4: 221-294(1962); E. B. Roche, Design of Biopharmaceutical Properties throughProdrugs and Analogs, Washington, DC: American PharmaceuticalAssociation (1977); A. A. Sinkula and S. H. Yalkowsky, Rationale fordesign of biologically reversible drug derivatives: prodrugs, J. Pharm.Sci., 64: 181-210 (1975). Use of the term “prodrug” usually implies acovalent link between a drug and a chemical moiety, though some authorsalso use it to characterize some forms of salts of the active drugmolecule. Although there is no strict universal definition of a prodrugitself, and the definition may vary from author to author, prodrugs cangenerally be defined as pharmacologically less active chemicalderivatives that can be converted in vivo, enzymatically ornonenzymatically, to the active, or more active, drug molecules thatexert a therapeutic, prophylactic or diagnostic effect. Sinkula andYalkowsky, above; V. J. Stella et al., Prodrugs: Do they have advantagesin clinical practice?, Drugs, 29: 455-473 (1985).

The terms “polymer” and “polymeric” refer to compounds that are theproduct of a polymerization reaction. These terms are inclusive ofhomopolymers (i.e., polymers obtained by polymerizing one type ofmonomer by either chain or condensation polymers), copolymers (i.e.,polymers obtained by polymerizing two or more different types ofmonomers by either chain or condensation polymers), condensationpolymers (polymers made from condensation polymerization, terpolymers,etc., including random (by either chain or condensation polymers),alternating (by either chain or condensation polymers), block (by eitherchain or condensation polymers), graft, dendritic, crosslinked and anyother variations thereof.

As used herein, the term “implantable” refers to the attribute of beingimplantable in a mammal (e.g., a human being or patient) that meets themechanical, physical, chemical, biological, and pharmacologicalrequirements of a device provided by laws and regulations of agovernmental agency (e.g., the U.S. FDA) such that the device is safeand effective for use as indicated by the device. As used herein, an“implantable device” may be any suitable substrate that can be implantedin a human or non-human animal. Examples of implantable devices include,but are not limited to, self-expandable stents, balloon-expandablestents, coronary stents, peripheral stents, stent-grafts, catheters,other expandable tubular devices for various bodily lumen or orifices,grafts, vascular grafts, arterio-venous grafts, by-pass grafts,pacemakers and defibrillators, leads and electrodes for the preceding,artificial heart valves, anastomotic clips, arterial closure devices,patent foramen ovale closure devices, cerebrospinal fluid shunts, andparticles (e.g., drug-eluting particles, microparticles andnanoparticles). The stents may be intended for any vessel in the body,including neurological, carotid, vein graft, coronary, aortic, renal,iliac, femoral, popliteal vasculature, and urethral passages. Animplantable device can be designed for the localized delivery of atherapeutic agent. A medicated implantable device may be constructed inpart, e.g., by coating the device with a coating material containing atherapeutic agent. The body of the device may also contain a therapeuticagent.

An implantable device can be fabricated with a coating containingpartially or completely a biodegradable/bioabsorbable/bioerodablepolymer, a biostable polymer, or a combination thereof. An implantabledevice itself can also be fabricated partially or completely from abiodegradable/bioabsorbable/bioerodable polymer, a biostable polymer, ora combination thereof.

As used herein, a material that is described as a layer or a film (e.g.,a coating) “disposed over” an indicated substrate (e.g., an implantabledevice) refers to, e.g., a coating of the material deposited directly orindirectly over at least a portion of the surface of the substrate.Direct depositing means that the coating is applied directly to theexposed surface of the substrate. Indirect depositing means that thecoating is applied to an intervening layer that has been depositeddirectly or indirectly over the substrate. In some embodiments, the terma “layer” or a “film” excludes a film or a layer formed on anon-implantable device.

In the context of a stent, “delivery” refers to introducing andtransporting the stent through a bodily lumen to a region, such as alesion, in a vessel that requires treatment. “Deployment” corresponds tothe expanding of the stent within the lumen at the treatment region.Delivery and deployment of a stent are accomplished by positioning thestent about one end of a catheter, inserting the end of the catheterthrough the skin into a bodily lumen, advancing the catheter in thebodily lumen to a desired treatment location, expanding the stent at thetreatment location, and removing the catheter from the lumen.

Generally, hydrophobicity of a polymer can be gauged using theHildebrand solubility parameter, δ. The term “Hildebrand solubilityparameter” refers to a parameter measuring the cohesion of a substance.The δ parameter is determined as follows:

δ=(ΔE/V)^(1/2)

where δ is the solubility parameter, (cal/cm³)^(1/2);

-   ΔE is the energy of vaporization, cal/mole; and-   V is the molar volume, cm³/mole.

Whichever polymer in the polymer blend has lower δ value compared to theδ value of the other polymer in the blend is designated as a hydrophobicpolymer, and the polymer with higher δ value is designated ashydrophilic. If more than two polymers are used in the blend, then eachcan be ranked in order of its δ value. For the practice of the presentinvention, the value of δ of a particular polymer is inconsequential forclassifying a polymer as hydrophobic or hydrophilic so long as thedifference in the δ values of the two polymers is sufficient to allowthe hydrophilic polymer to migrate or bloom to the surface as describedbelow. In one exemplary embodiment, the δ value defining the boundarybetween the hydrophobic and hydrophilic components of the polymer blendcan be about 11(cal/cm³)^(1/2).

Biologically Active Agents

In some embodiments, the implantable device described herein canoptionally include at least one biologically active (“bioactive”) agent.The at least one bioactive agent can include any substance capable ofexerting a therapeutic, prophylactic or diagnostic effect for a patient.

Examples of suitable bioactive agents include, but are not limited to,synthetic inorganic and organic compounds, proteins and peptides,polysaccharides and other sugars, lipids, and DNA and RNA nucleic acidsequences having therapeutic, prophylactic or diagnostic activities.Nucleic acid sequences include genes, antisense molecules that bind tocomplementary DNA to inhibit transcription, and ribozymes. Some otherexamples of other bioactive agents include antibodies, receptor ligands,enzymes, adhesion peptides, blood clotting factors, inhibitors or clotdissolving agents such as streptokinase and tissue plasminogenactivator, antigens for immunization, hormones and growth factors,oligonucleotides such as antisense oligonucleotides and ribozymes andretroviral vectors for use in gene therapy. The bioactive agents couldbe designed, e.g., to inhibit the activity of vascular smooth musclecells. They could be directed at inhibiting abnormal or inappropriatemigration and/or proliferation of smooth muscle cells to inhibitrestenosis.

In certain embodiments, optionally in combination with one or more otherembodiments described herein, the implantable device can include atleast one biologically active agent selected from antiproliferative,antineoplastic, antimitotic, anti-inflammatory, antiplatelet,anticoagulant, antifibrin, antithrombin, antibiotic, antiallergic andantioxidant substances.

An antiproliferative agent can be a natural proteineous agent such as acytotoxin or a synthetic molecule. Examples of antiproliferativesubstances include, but are not limited to, actinomycin D or derivativesand analogs thereof (manufactured by Sigma-Aldrich, or COSMEGEN®available from Merck) (synonyms of actinomycin D include dactinomycin,actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁); alltaxoids such as taxols, docetaxel, and paclitaxel and derivativesthereof; all olimus drugs such as macrolide antibiotics, rapamycin,everolimus, structural derivatives and functional analogues ofrapamycin, structural derivatives and functional analogues ofeverolimus, FKBP-12 mediated mTOR inhibitors, biolimus, perfenidone,prodrugs thereof, co-drugs thereof, and combinations thereof. Examplesof rapamycin derivatives include, but are not limited to,40-O-(2-hydroxy)ethyl-rapamycin (trade name everolimus from Novartis),40-O-(2-ethoxy)ethyl-rapamycin (biolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus, manufactured by AbbottLabs.), prodrugs thereof, co-drugs thereof, and combinations thereof

An anti-inflammatory drug can be a steroidal anti-inflammatory drug, anonsteroidal anti-inflammatory drug (NSAID), or a combination thereof.Examples of anti-inflammatory drugs include, but are not limited to,alclofenac, alclometasone dipropionate, algestone acetonide, alphaamylase, amcinafal, amcinafide, amfenac sodium, amiprilosehydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazidedisodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains,broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen,clobetasol, clobetasol propionate, clobetasone butyrate, clopirac,cloticasone propionate, cormethasone acetate, cortodoxone, deflazacort,desonide, desoximetasone, dexamethasone, dexamethasone acetate,dexamethasone dipropionate, diclofenac potassium, diclofenac sodium,diflorasone diacetate, diflumidone sodium, diflunisal, difluprednate,diftalone, dimethyl sulfoxide, drocinonide, endrysone, enlimomab,enolicam sodium, epirizole, etodolac, etofenamate, felbinac, fenamole,fenbufen, fenclofenac, fenclorac, fendosal, fenpipalone, fentiazac,flazalone, fluazacort, flufenamic acid, flumizole, flunisolide acetate,flunixin, flunixin meglumine, fluocortin butyl, fluorometholone acetate,fluquazone, flurbiprofen, fluretofen, fluticasone propionate,furaprofen, furobufen, halcinonide, halobetasol propionate, halopredoneacetate, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol,ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxole,intrazole, isoflupredone acetate, isoxepac, isoxicam, ketoprofen,lofemizole hydrochloride, lomoxicam, loteprednol etabonate,meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate,mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate,momiflumate, nabumetone, naproxen, naproxen sodium, naproxol, nimazone,olsalazine sodium, orgotein, orpanoxin, oxaprozin, oxyphenbutazone,paranyline hydrochloride, pentosan polysulfate sodium, phenbutazonesodium glycerate, pirfenidone, piroxicam, piroxicam cinnamate, piroxicamolamine, pirprofen, prednazate, prifelone, prodolic acid, proquazone,proxazole, proxazole citrate, rimexolone, romazarit, salcolex,salnacedin, salsalate, sanguinarium chloride, seclazone, sermetacin,sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate,tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide,tetrydamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium,triclonide, triflumidate, zidometacin, zomepirac sodium, aspirin(acetylsalicylic acid), salicylic acid, corticosteroids,glucocorticoids, tacrolimus, pimecorlimus, prodrugs thereof, co-drugsthereof, and combinations thereof.

Alternatively, the anti-inflammatory agent can be a biological inhibitorof pro-inflammatory signaling molecules. Anti-inflammatory biologicalagents include antibodies to such biological inflammatory signalingmolecules.

In addition, the bioactive agents can be other than antiproliferative oranti-inflammatory agents. The bioactive agents can be any agent that isa therapeutic, prophylactic or diagnostic agent. In some embodiments,such agents can be used in combination with antiproliferative oranti-inflammatory agents. These bioactive agents can also haveantiproliferative and/or anti-inflammmatory properties or can have otherproperties such as antineoplastic, antimitotic, cystostatic,antiplatelet, anticoagulant, antifibrin, antithrombin, antibiotic,antiallergic, and/or antioxidant properties.

Examples of antineoplastics and/or antimitotics include, but are notlimited to, paclitaxel (e.g., TAXOL® available from Bristol-MyersSquibb), docetaxel (e.g., Taxotere® from Aventis), methotrexate,azathioprine, vincristine, vinblastine, fluorouracil, doxorubicinhydrochloride (e.g., Adriamycin® from Pfizer), and mitomycin (e.g.,Mutamycin® from Bristol-Myers Squibb).

Examples of antiplatelet, anticoagulant, antifibrin, and antithrombinagents that can also have cytostatic or antiproliferative propertiesinclude, but are not limited to, sodium heparin, low molecular weightheparins, heparinoids, hirudin, argatroban, forskolin, vapiprost,prostacyclin and prostacyclin analogues, dextran,D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole,glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody,recombinant hirudin, thrombin inhibitors such as ANGIOMAX™ (bivalirudin,from Biogen), calcium channel blockers (e.g., nifedipine), colchicine,fibroblast growth factor (FGF) antagonists, fish oil (e.g., omega3-fatty acid), histamine antagonists, lovastatin (a cholesterol-loweringdrug that inhibits HMG-CoA reductase, brand name Mevacor® from Merck),monoclonal antibodies (e.g., those specific for platelet-derived growthfactor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors,prostaglandin inhibitors, suramin, serotonin blockers, steroids,thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitricoxide or nitric oxide donors, super oxide dismutases, super oxidedismutase mimetics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), estradiol, anticancer agents, dietary supplements suchas various vitamins, and a combination thereof.

Examples of cytostatic substances include, but are not limited to,angiopeptin, angiotensin converting enzyme inhibitors such as captopril(e.g., Capoten® and Capozide® from Bristol-Myers Squibb), cilazapril andlisinopril (e.g., Prinivil® and Prinzide® from Merck).

Examples of antiallergic agents include, but are not limited to,permirolast potassium. Examples of antioxidant substances include, butare not limited to, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO). Other bioactive agents include anti-infectives such asantiviral agents; analgesics and analgesic combinations; anorexics;antihelmintics; antiarthritics, antiasthmatic agents; anticonvulsants;antidepressants; antidiuretic agents; antidiarrheals; antihistamines;antimigrain preparations; antinauseants; antiparkinsonism drugs;antipruritics; antipsychotics; antipyretics; antispasmodics;anticholinergics; sympathomimetics; xanthine derivatives; cardiovascularpreparations including calcium channel blockers and beta-blockers suchas pindolol and antiarrhythmics; antihypertensives; diuretics;vasodilators including general coronary vasodilators; peripheral andcerebral vasodilators; central nervous system stimulants; cough and coldpreparations, including decongestants; hypnotics; immunosuppressives;muscle relaxants; parasympatholytics; psychostimulants; sedatives;tranquilizers; naturally derived or genetically engineered lipoproteins;and restenoic reducing agents.

Other biologically active agents that can be used includealpha-interferon, genetically engineered epithelial cells, tacrolimusand dexamethasone.

A “prohealing” drug or agent, in the context of a blood-contactingimplantable device, refers to a drug or agent that has the property thatit promotes or enhances re-endothelialization of arterial lumen topromote healing of the vascular tissue. The portion(s) of an implantabledevice (e.g., a stent) containing a prohealing drug or agent canattract, bind, and eventually become encapsulated by endothelial cells(e.g., endothelial progenitor cells). The attraction, binding, andencapsulation of the cells will reduce or prevent the formation ofemboli or thrombi due to the loss of the mechanical properties thatcould occur if the stent was insufficiently encapsulated. The enhancedre-endothelialization can promote the endothelialization at a ratefaster than the loss of mechanical properties of the stent.

The prohealing drug or agent can be dispersed in the body of thebioabsorbable polymer substrate or scaffolding. The prohealing drug oragent can also be dispersed within a bioabsorbable polymer coating overa surface of an implantable device (e.g., a stent).

“Endothelial progenitor cells” refer to primitive cells made in the bonemarrow that can enter the bloodstream and go to areas of blood vesselinjury to help repair the damage. Endothelial progenitor cells circulatein adult human peripheral blood and are mobilized from bone marrow bycytokines, growth factors, and ischemic conditions. Vascular injury isrepaired by both angiogenesis and vasculogenesis mechanisms. Circulatingendothelial progenitor cells contribute to repair of injured bloodvessels mainly via a vasculogenesis mechanism.

In some embodiments, the prohealing drug or agent can be an endothelialcell (EDC)-binding agent. In certain embodiments, the EDC-binding agentcan be a protein, peptide or antibody, which can be, e.g., one ofcollagen type 1, a 23 peptide fragment known as single chain Fv fragment(scFv A5), a junction membrane protein vascular endothelial(VE)-cadherin, and combinations thereof. Collagen type 1, when bound toosteopontin, has been shown to promote adhesion of endothelial cells andmodulate their viability by the down regulation of apoptotic pathways.S. M. Martin, et al., J. Biomed. Mater. Res., 70A:10-19 (2004).Endothelial cells can be selectively targeted (for the targeted deliveryof immunoliposomes) using scFv A5. T. Volkel, et al., Biochimica etBiophysica Acta, 1663:158-166 (2004). Junction membrane protein vascularendothelial (VE)-cadherin has been shown to bind to endothelial cellsand down regulate apoptosis of the endothelial cells. R. Spagnuolo, etal., Blood, 103:3005-3012 (2004).

In a particular embodiment, the EDC-binding agent can be the activefragment of osteopontin,(Asp-Val-Asp-Val-Pro-Asp-Gly-Asp-Ser-Leu-Ala-Try-Gly). Other EDC-bindingagents include, but are not limited to, EPC (epithelial cell)antibodies, RGD peptide sequences, RGD mimetics, and combinationsthereof.

In further embodiments, the prohealing drug or agent can be a substanceor agent that attracts and binds endothelial progenitor cells.Representative substances or agents that attract and bind endothelialprogenitor cells include antibodies such as CD-34, CD-133 and vegf type2 receptor. An agent that attracts and binds endothelial progenitorcells can include a polymer having nitric oxide donor groups.

The foregoing biologically active agents are listed by way of exampleand are not meant to be limiting. Other biologically active agents thatare currently available or that may be developed in the future areequally applicable.

In a more specific embodiment, optionally in combination with one ormore other embodiments described herein, the implantable device of theinvention comprises at least one biologically active agent selected frompaclitaxel, docetaxel, estradiol, nitric oxide donors, super oxidedismutases, super oxide dismutase mimics,4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO),tacrolimus, dexamethasone, rapamycin, rapamycin derivatives,40-O-(2-hydroxy)ethyl-rapamycin (everolimus),40-O-(2-ethoxy)ethyl-rapamycin (biolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus), pimecrolimus, imatinibmesylate, midostaurin, clobetasol, progenitor cell-capturing antibodies,prohealing drugs, prodrugs thereof, co-drugs thereof, and a combinationthereof In a particular embodiment, the bioactive agent is everolimus.In another specific embodiment, the bioactive agent is clobetasol.

An alternative class of drugs would be p-para-α-agonists for increasedlipid transportation, examples include feno fibrate.

In some embodiments, optionally in combination with one or more otherembodiments described herein, the at least one biologically active agentspecifically cannot be one or more of any of the bioactive drugs oragents described herein.

Coating Construct

According to some embodiments of the invention, optionally incombination with one or more other embodiments described herein, acoating disposed over an implantable device (e.g., a stent) can includea semi-crystalline polymer described herein in a layer according to anydesign of a coating. The coating can be a multi-layer structure thatincludes at least one reservoir layer, which is layer (2) describedbelow, and can include any of the following (1), (3), (4) and (5) layersor combination thereof:

-   -   (1) a primer layer; (optional)    -   (2) a reservoir layer (also referred to “matrix layer” or “drug        matrix”), which can be a drug-polymer layer including at least        one polymer (drug-polymer layer) or, alternatively, a        polymer-free drug layer;    -   (3) a release control layer (also referred to as a        “rate-limiting layer”) (optional);    -   (4) a topcoat layer; and/or (optional);    -   (5) a finishing coat layer. (optional).

In some embodiments, a coating of the invention can include two or morereservoir layers described above, each of which can include a bioactiveagent described herein.

Each layer of a stent coating can be disposed over the implantabledevice (e.g., a stent) by dissolving the semi-crystalline polymer,optionally with one or more other polymers, in a solvent, or a mixtureof solvents, and disposing the resulting coating solution over the stentby spraying or immersing the stent in the solution. After the solutionhas been disposed over the stent, the coating is dried by allowing thesolvent to evaporate. The process of drying can be accelerated if thedrying is conducted at an elevated temperature. The complete stentcoating can be optionally annealed at a temperature between about 40° C.and about 150° C., e.g., 80° C., for a period of time between about 5minutes and about 60 minutes, if desired, to allow for crystallizationof the polymer coating, and/or to improve the thermodynamic stability ofthe coating.

To incorporate a bioactive agent (e.g., a drug) into the reservoirlayer, the drug can be combined with the polymer solution that isdisposed over the implantable device as described above. Alternatively,if it is desirable a polymer-free reservoir can be made. To fabricate apolymer-free reservoir, the drug can be dissolved in a suitable solventor mixture of solvents, and the resulting drug solution can be disposedover the implantable device (e.g., stent) by spraying or immersing thestent in the drug-containing solution.

Instead of introducing a drug via a solution, the drug can be introducedas a colloid system, such as a suspension in an appropriate solventphase. To make the suspension, the drug can be dispersed in the solventphase using conventional techniques used in colloid chemistry. Dependingon a variety of factors, e.g., the nature of the drug, those havingordinary skill in the art can select the solvent to form the solventphase of the suspension, as well as the quantity of the drug to bedispersed in the solvent phase. Optionally, a surfactant can be added tostabilize the suspension. The suspension can be mixed with a polymersolution and the mixture can be disposed over the stent as describedabove. Alternatively, the drug suspension can be disposed over the stentwithout being mixed with the polymer solution.

The drug-polymer layer can be applied directly or indirectly over atleast a portion of the stent surface to serve as a reservoir for atleast one bioactive agent (e.g., drug) that is incorporated into thereservoir layer. The optional primer layer can be applied between thestent and the reservoir to improve the adhesion of the drug-polymerlayer to the stent. The optional topcoat layer can be applied over atleast a portion of the reservoir layer and serves as a rate-limitingmembrane that helps to control the rate of release of the drug. In oneembodiment, the topcoat layer can be essentially free from any bioactiveagents or drugs. If the topcoat layer is used, the optional finishingcoat layer can be applied over at least a portion of the topcoat layerfor further control of the drug-release rate and for improving thebiocompatibility of the coating. Without the topcoat layer, thefinishing coat layer can be deposited directly on the reservoir layer.

Sterilization of a coated medical device generally involves a processfor inactivation of micropathogens. Such processes are well known in theart. A few examples are e-beam, ETO sterilization, and irradiation.Most, if not all, of these processes can involve an elevatedtemperature. For example, ETO sterilization of a coated stent generallyinvolves heating above 50° C. at humidity levels reaching up to 100% forperiods of a few hours up to 24 hours. A typical EtO cycle would havethe temperature in the enclosed chamber to reach as high as above 50° C.within the first 3-4 hours then and fluctuate between 40° C. to 50° C.for 17-18 hours while the humidity would reach the peak at 100% andmaintain above 80% during the fluctuation time of the cycle.

The process of the release of a drug from a coating having both topcoatand finishing coat layers includes at least three steps. First, the drugis absorbed by the polymer of the topcoat layer at the drug-polymerlayer/topcoat layer interface. Next, the drug diffuses through thetopcoat layer using the void volume between the macromolecules of thetopcoat layer polymer as pathways for migration. Next, the drug arrivesat the topcoat layer/finishing layer interface. Finally, the drugdiffuses through the finishing coat layer in a similar fashion, arrivesat the outer surface of the finishing coat layer, and desorbs from theouter surface. At this point, the drug is released into the blood vesselor surrounding tissue. Consequently, a combination of the topcoat andfinishing coat layers, if used, can serve as a rate-limiting barrier.The drug can be released by virtue of the degradation, dissolution,and/or erosion of the layer(s) forming the coating, or via migration ofthe drug through the semi-crystalline polymeric layer(s) into a bloodvessel or tissue.

In one embodiment, any or all of the layers of the stent coating can bemade of a semi-crystalline polymer described herein, optionally havingthe properties of being biologicallydegradable/erodable/absorbable/resorbable, non-degradable/biostablepolymer, or a combination thereof. In another embodiment, the outermostlayer of the coating can be limited to a semi-crystalline polymer asdefined above.

To illustrate in more detail, in a stent coating having all four layersdescribed above (i.e., the primer, the reservoir layer, the topcoatlayer and the finishing coat layer), the outermost layer is thefinishing coat layer, which can be made of a semi-crystalline polymerdescribed herein and optionally having the properties of beingbiodegradable or, biostable, or being mixed with an amorphous polymer.The remaining layers (i.e., the primer, the reservoir layer and thetopcoat layer) optionally having the properties of being biodegradableor, biostable, or being mixed with an amorphous polymer. The polymer(s)in a particular layer may be the same as or different than those in anyof the other layers, as long as the layer on the outside of anotherbioabsorbable should preferably also be bioabsorbable and degrade at asimilar or faster relative to the inner layer. As another illustration,the coating can include a single matrix layer comprising a polymerdescribed herein and a drug.

If a finishing coat layer is not used, the topcoat layer can be theoutermost layer and should be made of a semi-crystalline polymerdescribed herein and optionally having the properties of beingbiodegradable or, biostable, or being mixed with an amorphous polymer.In this case, the remaining layers (i.e., the primer and the reservoirlayer) optionally can also be fabricated of a semi-crystalline polymerdescribed herein and optionally having the properties of beingbiodegradable or, biostable, or being mixed with an amorphous polymerThe polymer(s) in a particular layer may be the same as or differentthan those in any of the other layers, as long as the outside of anotherbioabsorbable should preferably also be bioabsorbable and degrade at asimilar or faster relative to the inner layer.

If neither a finishing coat layer nor a topcoat layer is used, the stentcoating could have only two layers—the primer and the reservoir. In sucha case, the reservoir is the outermost layer of the stent coating andshould be made of a semi-crystalline polymer described herein andoptionally having the properties of being biodegradable or, biostable,or being mixed with an amorphous polymer. The primer optionally can alsobe fabricated of a semi-crystalline polymer described herein andoptionally one or more biodegradable polymer(s), biostable polymer(s),or a combination thereof. The two layers may be made from the same ordifferent polymers, as long as the layer on the outside of anotherbioabsorbable should preferably also be bioabsorbable and degrade at asimilar or faster relative to the inner layer.

Any layer of a coating can contain any amount of a semi-crystallinepolymer described herein and optionally having the properties of beingbiodegradable or, biostable, or being mixed with an amorphous polymer.Non-limiting examples of bioabsorbable polymers and biocompatiblepolymers include poly(N-vinyl pyrrolidone); polydioxanone;polyorthoesters; polyanhydrides; poly(glycolic acid); poly(glycolicacid-co-trimethylene carbonate); polyphosphoesters; polyphosphoesterurethanes; poly(amino acids); poly(trimethylene carbonate);poly(iminocarbonates); co-poly(ether-esters); polyalkylene oxalates;polyphosphazenes; biomolecules, e.g., fibrin, fibrinogen, cellulose,cellophane, starch, collagen, hyaluronic acid, and derivatives thereof(e.g., cellulose acetate, cellulose butyrate, cellulose acetatebutyrate, cellulose nitrate, cellulose propionate, cellulose ethers, andcarboxymethyl cellulose), polyurethane,; polyesters, polycarbonates,polyurethanes, poly(L-lactic acid-co-caprolactone) (PLLA-CL),poly(D-lactic acid-co-caprolactone) (PDLA-CL), poly(DL-lacticacid-co-caprolactone) (PDLLA-CL), poly(D-lactic acid-glycolic acid(PDLA-GA), poly(L-lactic acid-glycolic acid (PLLA-GA), poly(DL-lacticacid-glycolic acid (PDLLA-GA), poly(D-lacticacid-co-glycolide-co-caprolactone) (PDLA-GA-CL), poly(L-lacticacid-co-glycolide-co-caprolactone) (PLLA-GA-CL), poly(DL-lacticacid-co-glycolide-co-caprolactone) (PDLLA-GA-CL), poly(L-lacticacid-co-caprolactone) (PLLA-CL), poly(D-lactic acid-co-caprolactone)(PDLA-CL), poly(DL-lactic acid-co-caprolactone) (PDLLA-CL),poly(glycolide-co-caprolactone) (PGA-CL), or any copolymers thereof.

Any layer of a stent coating can also contain any amount of anon-degradable polymer, or a blend of more than one such polymer as longas it is not mixed with a bioabsorbable polymer or any layer underneaththe non-degradable layer comprise a bioabsorbable polymer. Non-limitingexamples of non-degradable polymers include methylmethacrylate,ethylmethacrylate, butylmethacrylate, 2-ethylhexylmethacrylate,laurylmethacrylate, hydroxyl ethyl methacrylate, polyethylene glycol(PEG) acrylate, PEG methacrylate,2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone,methacrylic acid, acrylic acid, hydroxypropyl methacrylate,hydroxypropylmethacrylamide, 3-trimethylsilylpropyl methacrylate, andcopolymers thereof.

Method of Fabricating Implantable Device

Other embodiments of the invention, optionally in combination with oneor more other embodiments described herein, are drawn to a method offabricating an implantable device. In one embodiment, the methodcomprises forming the implantable device of a material containing abiodegradable or biostable polymer or copolymer.

Under the method, a portion of the implantable device or the wholedevice itself can be formed of the material containing a biodegradableor biostable polymer or copolymer. The method can deposit a coatinghaving a range of thickness over an implantable device. In certainembodiments, the method deposits over at least a portion of theimplantable device a coating that has a thickness of ≦about 30 micron,or ≦about 20 micron, or ≦about 10 micron, or ≦about 5 micron.

In certain embodiments, the method is used to fabricate an implantabledevice selected from stents, grafts, stent-grafts, catheters, leads andelectrodes, clips, shunts, closure devices, valves, and particles. In aspecific embodiment, the method is used to fabricate a stent.

In some embodiments, to form an implantable device formed from apolymer, a polymer or copolymer optionally including at least onebioactive agent described herein can be formed into a polymer construct,such as a tube or sheet that can be rolled or bonded to form a constructsuch as a tube. An implantable device can then be fabricated from theconstruct. For example, a stent can be fabricated from a tube by lasermachining a pattern into the tube. In another embodiment, a polymerconstruct can be formed from the polymeric material of the inventionusing an injection-molding apparatus.

Non-limiting examples of polymers, which may or may not be thesemi-crystalline polymers defined above, that can be used to fabricatean implantable device include poly(N-acetylglucosamine) (Chitin),Chitosan, poly(hydroxyvalerate), poly(lactide-co-glycolide),poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate),polyorthoester, polyanhydride, poly(L-lactic acid-co-caprolactone)(PLLA-CL), poly(D-lactic acid-co-caprolactone) (PDLA-CL), poly(DL-lacticacid-co-caprolactone) (PDLLA-CL), poly(D-lactic acid-glycolic acid(PDLA-GA), poly(L-lactic acid-glycolic acid (PLLA-GA), poly(DL-lacticacid-glycolic acid (PDLLA-GA), poly(D-lacticacid-co-glycolide-co-caprolactone) (PDLA-GA-CL), poly(L-lacticacid-co-glycolide-co-caprolactone) (PLLA-GA-CL), poly(DL-lacticacid-co-glycolide-co-caprolactone) (PDLLA-GA-CL), poly(L-lacticacid-co-caprolactone) (PLLA-CL), poly(D-lactic acid-co-caprolactone)(PDLA-CL), poly(DL-lactic acid-co-caprolactone) (PDLLA-CL),poly(glycolide-co-caprolactone) (PGA-CL), poly(thioesters),poly(trimethylene carbonate), polyethylene amide, polyethylene acrylate,poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters)(e.g., PEO/PLA), polyphosphazenes, biomolecules (e.g., fibrin,fibrinogen, cellulose, starch, collagen and hyaluronic acid),polyurethanes, silicones, polyesters, polyolefins, polyisobutylene andethylene-alphaolefin copolymers, acrylic polymers and copolymers otherthan polyacrylates, vinyl halide polymers and copolymers (e.g.,polyvinyl chloride), polyvinyl ethers (e.g., polyvinyl methyl ether),polyvinylidene halides (e.g., polyvinylidene chloride),polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (e.g.,polystyrene), polyvinyl esters (e.g., polyvinyl acetate),acrylonitrile-styrene copolymers, ABS resins, polyamides (e.g., Nylon 66and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides,polyethers, polyurethanes, rayon, rayon-triacetate, cellulose andderivates thereof (e.g., cellulose acetate, cellulose butyrate,cellulose acetate butyrate, cellophane, cellulose nitrate, cellulosepropionate, cellulose ethers, and carboxymethyl cellulose), andcopolymers thereof.

Additional representative examples of polymers that may be suited forfabricating an implantable device include ethylene vinyl alcoholcopolymer (commonly known by the generic name EVOH or by the trade nameEVAL®), poly(butyl methacrylate), poly(vinylidenefluoride-co-hexafluoropropylene) (e.g., SOLEF® 21508, available fromSolvay Solexis PVDF of Thorofare, N.J.), polyvinylidene fluoride(otherwise known as KYNAR®, available from Atofina Chemicals ofPhiladelphia, Pennsylvania),poly(tetrafluoroethylene-co-hexafluoropropylene-co-vinylidene fluoride),ethylene-vinyl acetate copolymers, and polyethylene glycol.

Method of Treating or Preventing Disorders

An implantable device according to the present invention can be used totreat, prevent or diagnose various conditions or disorders. Examples ofsuch conditions or disorders include, but are not limited to,atherosclerosis, thrombosis, restenosis, hemorrhage, vasculardissection, vascular perforation, vascular aneurysm, vulnerable plaque,chronic total occlusion, patent foramen ovale, claudication, anastomoticproliferation of vein and artificial grafts, arteriovenous anastamoses,bile duct obstruction, ureter obstruction and tumor obstruction. Aportion of the implantable device or the whole device itself can beformed of the material, as described herein. For example, the materialcan be a coating disposed over at least a portion of the device.

In certain embodiments, optionally in combination with one or more otherembodiments described herein, the inventive method treats, prevents ordiagnoses a condition or disorder selected from atherosclerosis,thrombosis, restenosis, hemorrhage, vascular dissection, vascularperforation, vascular aneurysm, vulnerable plaque, chronic totalocclusion, patent foramen ovale, claudication, anastomotic proliferationof vein and artificial grafts, arteriovenous anastamoses, bile ductobstruction, ureter obstruction and tumor obstruction. In a particularembodiment, the condition or disorder is atherosclerosis, thrombosis,restenosis or vulnerable plaque.

In one embodiment of the method, optionally in combination with one ormore other embodiments described herein, the implantable device isformed of a material or includes a coating containing at least onebiologically active agent selected from paclitaxel, docetaxel,estradiol, nitric oxide donors, super oxide dismutases, super oxidedismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycinderivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus),40-O-(2-ethoxy)ethyl-rapamycin (biolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus), pimecrolimus, imatinibmesylate, midostaurin, clobetasol, progenitor cell-capturing antibodies,prohealing drugs, fenofibrate, prodrugs thereof, co-drugs thereof, and acombination thereof.

In certain embodiments, optionally in combination with one or more otherembodiments described herein, the implantable device used in the methodis selected from stents, grafts, stent-grafts, catheters, leads andelectrodes, clips, shunts, closure devices, valves, and particles. In aspecific embodiment, the implantable device is a stent.

EXAMPLE 1

Coatings comprising a PEG-PLGA IPN with a weight average molecularweight (Mw) of about 34 KDa were formed on Vision stents (3mm×12 mm,available from Abbott Vascular, Santa Clara, Calif.) with formulationsdescribed below. The coatings showed acceptable coating integrity afterE-beam (Scanning Electron Microscope (SEM) images not shown) and areasonable controlled release of the everolimus (Table 1).

Sample formulation:

drug:polymer (D:P)=1:3;

solvent: 100% acetone;

dose: 100 μg/cm² dose;

sterilization: E-beam

TABLE 1 Total Content and release rate results Total Drug releaseContent (%), rate (RR) RR day 3 (%), Sample Lot# n = 3 day 1 (5), n = 3n = 3 PEG-IPN with 081107 73.8 ± 5.3 68.1 ± 4.7 81.1 ± 1.3 D:P = 1:3

EXAMPLE 2

Coatings comprising various compositions of PEG in PEG-PLGA IPN with aweight average molecular weight (Mw) of about 34 KDa were formed onVision stents (3 mm×12 mm, available from Abbott Vascular, Santa Clara,Calif.) with formulations described below. The coatings showedacceptable coating integrity after E-beam (FIGS. 1A-1F) and release ratethat is dependent on the composition of the PEG in the IPN (FIG. 2).

Sample formulation:

drug:polymer (D:P)=1:2;

solvent: 100% acetone;

dose: 100 μg/cm² dose;

sterilization: E-beam

FIGS. 2A-B: Coating Integrity of PEG-IPN #1

2C-D: Coating integrity of PEG-IPN #2

2E-F: Coating integrity of PEG-IPN #3

While particular embodiments of the present invention have been shownand described, it will be obvious to those skilled in the art thatchanges and modifications can be made without departing from thisinvention in its broader aspects. Therefore, the appended claims are toencompass within their scope all such changes and modifications as fallwithin the true spirit and scope of this invention.

1. An implantable medical device comprising a coating, the coatingcomprising an interpenetrating network (IPN) or semi-IPN, wherein theIPN or semi-IPN comprises poly(ethylene glycol) (PEG) and an aliphaticpolyester copolymer.
 2. The implantable device of claim 1, wherein thealiphatic polyester copolymer comprises D,L-lactide or L-lactide.
 3. Theimplantable device of claim 1, wherein the aliphatic polyester copolymercomprises glycolide (GA).
 4. The implantable device of claim 1, whereinthe aliphatic polyester copolymer comprisespoly(lactide-co-glycolide-co-caprolactone) (PLGACL),poly(lactide-co-glycolide) (PLGA), or poly(butylene succinate).
 5. Theimplantable device of claim 1, wherein the IPN or semi-IPN comprisesfrom about 1% to about 40% PEG by mass of the IPN or semi-IPN.
 6. Theimplantable device of claim 1, wherein the IPN or semi-IPN comprisesfrom about 2% to about 25% PEG by mass of the IPN or semi-IPN.
 7. Theimplantable device of claim 1, wherein the IPN or semi-IPN comprisesfrom about 2% to about 10% PEG by mass of the IPN or semi-IPN.
 8. Theimplantable device of claim 1, wherein the aliphatic polyester copolymercomprises lactide and glycolide in a molar ratio of lactide to glycolideranging from about 50:50 to about 90:10.
 9. The implantable device ofclaim 1, wherein the aliphatic polyester copolymer comprises lactide andglycolide in a molar ratio of lactide to glycolide of about 75:25. 10.The implantable device of claim 1, wherein coating further comprises abioactive agent.
 11. The implantable device of claim 1, wherein coatingfurther comprises a bioactive agent, and wherein the bioactive agent andthe IPN or semi-IPN are in a weight ratio of the bioactive agent to theIPN or semi-IPN of about 1:1 to about 1:5.
 12. The implantable device ofclaim 1, wherein the coating further comprises a bioactive agentselected from the group consisting of paclitaxel, docetaxel, estradiol,17-beta-estradiol, nitric oxide donors, super oxide dismutases, superoxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, dexamethasoneacetate, rapamycin, rapamycin derivatives,40-O-(2-hydroxy)ethyl-rapamycin (everolimus),40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, Biolimus A9(Biosensors International, Singapore), AP23572 (Ariad Pharmaceuticals),γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin,feno fibrate, prodrugs thereof, co-drugs thereof, and combinationsthereof.
 13. The implantable device of claim 1, wherein the implantabledevice is a stent.
 14. A method, comprising implanting in a patient animplantable device according to claim 1.